Advaxis, a leader in developing cancer immunotherapies has announced it has been granted [b]Orphan Drug Designation[/b] from the [b]US Food and Drug Administration Office of Orphan Products Development[/b] for ADXS-HPV, its lead immunotherapy drug candidate, for the treatment of Stage II-IV invasive cervical cancer. The Orphan Drug Designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the US.
[link url=http://www.news-medical.net/news/20140502/FDA-grants-Orphan-Drug-Designation-to-Advaxis-ADXS-HPV-for-treatment-of-invasive-cervical-cancer.aspx]Full News-Medical report[/link]